DMRA
Damora Therapeutics, Inc. trades as DMRA and has a market capitalization of $1.76 B, making it the #2249 largest US-listed company by market value. This page tracks Damora Therapeutics, Inc. through 328 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-12 |
| New insider ownership | 3 | 2026-05-08 |
| Major company event | 8-K | 2026-05-04 |
| Annual report to shareholders | ARS | 2026-05-01 |
| Proxy statement | DEF 14A | 2026-04-29 |
The largest companies sharing Damora Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Damora Therapeutics, Inc. (DMRA) has a market capitalization of $1.76 B as of 2026-07-11, ranking #2249 among US-listed companies.
In its latest fiscal year Damora Therapeutics, Inc. reported a net loss of $209.84M.